SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is trending as investors monitor reports of a potential Japanese delegation visiting Greenland to evaluate rare earth opportunities, fueling hopes for strategic partnerships that could bypass Chinese supply chains. While the community remains divided on the pace of project development and communication, many shareholders are highlighting the stock's long-term potential as a critical component of Western defense and industrial supply independence.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is experiencing heightened activity and investor interest driven by persistent buyout rumors and significant trading volume, as the community debates whether the stock is undervalued given its product portfolio and cash position. Shareholders remain deeply divided, with some betting on a potential hostile takeover or acquisition while others express frustration over leadership and the stock's failure to maintain momentum.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as investors focus on the upcoming August PDUFA date and a key court hearing regarding distribution rights that could allow the company to pursue an independent US launch. The community is actively discussing the recent surge in short interest and the potential for a short squeeze, while debating how a favorable court ruling or FDA labeling outcome could expand the commercial value of their lead DMD therapy.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund (USO) is experiencing high volatility as traders react to conflicting reports regarding the status of the Strait of Hormuz and ongoing U.S.-Iran negotiations. The community is deeply divided between those betting on a rapid supply-driven price crash following potential de-escalation and those anticipating further spikes due to persistent geopolitical instability and tight energy inventories.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energy is experiencing heightened volatility and a sharp pullback as investors weigh index rebalancing pressures and recent project delays against its long-term role as a key infrastructure provider for AI data centers. The community remains deeply divided, with some traders viewing the decline as a major buying opportunity while others express caution regarding the stock's valuation and the broader sustainability of the power-infrastructure trade.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is facing intense selling pressure as investors grapple with significant dilution concerns, negative sentiment regarding its debt obligations, and fears that the company's aggressive accumulation strategy has become a liability. While some community members are actively hunting for a bottom and viewing the volatility as a potential entry point for a long-term Bitcoin proxy, others are aggressively shorting the stock, labeling it a potential bankruptcy risk due to its complex financial structure and reliance on unsustainable dividend payments.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending as retail investors speculate on potential inclusion in the Russell 1000 index, driving significant options activity and ongoing conflict between bullish sentiment and short sellers.

Ardelyx, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs. Its products include IBSRELA and XPHOZAH. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Ardelyx is trending as retail investors weigh the recent loss of a key Medicare reimbursement court case against the company's strong revenue growth and upcoming clinical milestones. The community is actively debating whether the stock is undervalued or if potential institutional sell-offs and the impact of competing therapies will continue to weigh on the share price in the near term.

Venture Global, Inc. engages in the provision of United States liquefied natural gas sourced from resource rich North American natural gas basins. It operates through the following segments: Calcasieu Project, Plaquemines Project, CP2 Project, and Sales and shipping. The company was founded by Michael Sabel and Robert Pender in 2023 and is headquartered in Arlington, VA.

Venture Global Inc. - Ordinary Shares - Class A

Venture Global Inc

Venture Global is trending as investors weigh strong operational fundamentals, such as expanded shipping agreements and infrastructure growth, against the persistent geopolitical instability in the Strait of Hormuz. While some community members remain focused on the potential for long-term cash flow from new contracts, active discussion is dominated by the volatility driven by conflicting headlines regarding U.S.-Iran diplomatic status and its subsequent impact on oil and gas supply chains.

FuboTV, Inc. is a consumer-first live TV streaming company with the mission of delivering premium sports, news and entertainment programming that offers greater choice, flexibility and value. The company was founded by David Gandler, Alberto Horihuela Suarez, and Sung Ho Choi on February 20, 2009 and is headquartered in New York, NY.

fuboTV Inc - Ordinary Shares - Class A

fuboTV Inc

FuboTV is seeing increased social media chatter following the announcement of a new distribution deal with NBCUniversal, which restores access to key channels including Telemundo ahead of the FIFA World Cup. While bulls highlight this partnership and the company's integration within the Disney ecosystem as critical growth catalysts, bears remain skeptical, frequently citing the stock's long-term downward performance and management's past share sales as primary points of concern.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ONC Stock Gains As BeOne Medicines Wins US Nod For BEQALZI In Rare Lymphoma

Equity

The FDA approved BEQALZI in the treatment of certain mantle cell lymphoma patients on Wednesday. 


Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?

Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?

SRPT Stock Clocks Highest Daily Gain In Nearly 8 Years After Rare Muscle Disorders Study Data But Wall Street's Not Wholly Convinced

Leerink analyst Joseph Schwartz said the initial data released by the company in genetic diseases DM1 and FSHD1 are "a bit of a mixed bag."


Sarepta Shares Rise As Company Begins Enrollment In Gene Therapy Safety Enhancement Study

Data from the study cohort is aimed at determining whether administering sirolimus prior to and after Elevidys infusion can help reduce risks associated with the gene therapy. 


 SNSE Stock Surges To 21-Month High – Everything To Know About Its Faeth Therapeutics Acquisition

The company said that the acquisition adds Faeth’s lead investigational therapy, PIKTOR, to its oncology portfolio.

Why Did SRPT Stock Rise 6% In Pre-Market Today?

The company announced positive three-year topline results from its EMBARK study evaluating ELEVIDYS, a gene therapy for ambulatory patients with DMD.

 

IBRX Stock Gains Pre-Market After A Volatile Trading Session Following Phase 2 Glioblastoma Trial Update: Retail Backs ImmunityBio’s Cancer Research

Patrick Soon Shiong, ImmunityBio’s founder, took to X on Saturday to clarify what the update signified.

First Trust Exchange-Traded Fund - First Trust NYSE Arca Biotechnology Index Fund

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$246.96
Prev Close	$242.17
Open	$242.08
Dividend Yield	N/A
50-Day Moving Average	$215.61
Beta	N/A
Avg. Volume	71,268.53
PE Ratio	N/A

52-Week High	$245.85
52-Week Low	$158.92
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

Feed

News

Sentiment

Fundamentals

Info

FBTFirst Trust Exchange-Traded Fund III - First Trust NYSE Arca Biotechnology Index Fund

Latest FBT News